Stephen J. Elledge
Co-Founder & Chairman of Scientific Advisory BoardDr. Stephen J. Elledge also known as Steve, Ph.D., is Co-Founder of Mirimus, Inc. Dr. Elledge is Scientific Advisory Board Member of CRISPR Therapeutics, Inc. Dr. Elledge is Member of Scientific Advisory Board of Infinity Bio, Inc. since October 2024. Dr. Elledge is a Founder at Maze Therapeutics, Inc. He is the Gregor Mendel Professor of Genetics and Medicine at Harvard Medical School and Brigham and Women's Hospital. Dr. Elledge is a Member of Scientific Advisory Board at Homology Medicines, Inc. He is Co-Founder of ImmuneID, Inc. and serves as its Scientific Advisory Board Chair. He also serves as Member of Strategic Advisory Board at Longwood Fund since December 2023. He is an Investigator with the Howard Hughes Medical Institute since 1993. He serves as a Member of Medical and Scientific Advisory Board at MPM Capital. He serves as Co-Founder & Chairman of Scientific Advisory Board at TScan Therapeutics, Inc. He joined MPM's advisory board in 2017 to help MPM continue to translate scientific innovations into positive clinical outcomes. Dr. Elledge serves as a Member of Scientific Advisory Board at CRISPR Therapeutics AG and Permeon Biologics, Inc. He was elected to the National Academy of Sciences, the American Academy of Arts and Sciences, the American Academy of Microbiology and the Institute of Medicine of the National Academy. Dr. Elledge is a leading authority on the mechanisms of DNA repair that are essential to CRISPR/Cas9 gene editing approaches. Dr. Elledge has published over 250 articles, which include groundbreaking contributions to the study of proteins and biochemical pathways that regulate the cell division cycle and how these pathways are usurped in human cancer. He served as the faculty at the Baylor College of Medicine in the Department of Biochemistry in 1989 prior to joining Harvard Medical School in 2003. He is widely cited for his many seminal contributions and in particular for his work on the mechanics of both cellular proliferation and senescence. Dr. Elledge has received numerous awards including the 2015 Albert Lasker Basic Medical Research Award for his body of work elucidating how cells sense DNA damage and initiate self-repair. He is also a leader in promoting new genetic technologies and designing methodologies to help researchers better analyze the development of various disorders including cancer, autoimmune diseases and neurodegenerative conditions. The recipient of numerous other awards including the 2017 Breakthrough Prize for Life Sciences for paradigm-shifting research and the 2015 Wiley Prize, he has also been a Helen Hay Whitney Fellow, an American Cancer Society Senior Fellow and a Pew Scholar. He has received awards for his research including the Michael E. Debakey Award, the Paul Mark's Prize in Cancer Research, the National Academy of Sciences Award in Molecular Biology, the Hans Siegrist International Prize and the Dickson Prize in Medicine. He received his B.S. in chemistry from the University of Illinois, his Ph.D. in biology from the Massachusetts Institute of Technology and performed post-doctoral studies in the Department of Biochemistry at Stanford University.
公司职务
- 公司名称TScan Therapeutics, Inc.股票代码TCRX职务Co-Founder & Chairman of Scientific Advisory Board共事同僚
- GMGavin MacBeathCEO, Principal Financial Officer, Principal Accounting Officer & Director
- SRStephen Richard BiggarIndependent Chair of the Board
- TKTomasz KulaCo-Founder & Member of Advisory Board
- ZZZoran ZdraveskiChief Legal & Strategy Officer and Company Secretary
- AHAnn HargravesChief Human Resources Officer
- KDKatina DortonIndependent Director
